Sterling Biotech Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2018. For the quarter, the company's revenue from operations was INR 949.474 million compared to INR 876.087 million for the same period a year ago. Net profit for the period was INR 369.665 million compared to loss of INR 1,680.202 million for the same period a year ago. Basic EPS (not annualized) was INR 1.36 against LPS of INR 6.17 for the same period a year ago. Diluted EPS (not annualized) was INR 0.86 against LPS of INR 6.17 for the same period a year ago. For the nine months, the company's revenue from operations was INR 2,605.770 million compared to INR 2,781.533 million for the same period a year ago. Net loss for the period was INR 24,083.648 million compared to INR 4,422.821 million for the same period a year ago. Basic LPS (not annualized) was INR 140.66 against INR 16.18 for the same period a year ago.